Home Shop LAG-3 (human) monoclonal antibody (17B4)

LAG-3 (human) monoclonal antibody (17B4)

ALX-804-806

Datasheet
Manual
SDS
CofA

Already have an account?

The lymphocyte activation gene-3 (LAG-3, CD223), a member of the immunoglobulin superfamily (IgSF) related to CD4, binds to the major histocompatibility complex (MHC) class II molecules but with higher affinity than CD4. Several alternative mRNA splice-variants of human LAG-3 have been described, two of them encoding potential secreted forms: LAG-3V1 (i.e. the D1-D2 domains of the protein, 36 kDa) and LAG-3V3 (D1-D3, 52 kDa). The longer form was detected by ELISA in the serum of healthy individuals as well as of tuberculosis patients with a favorable outcome. LAG-3 expression by T cell clones correlated with IFN-γ production, and hence soluble LAG-3 has been suggested as a serological marker of Th1 responses.

Shipping: Available products typically ship within 24/48h, via priority shipping.

Do you need support? Contact Customer Service or Technical Support.

Online Account
Access or Create Your Account

This antibody is covered by our Worry-Free Guarantee.

LAG-3 (human) monoclonal antibody (17B4) Western blot — Western blot analysis of LAG-3 mAb (17B4) (Prod. No. ALX-804-806): Lane 1: MW marker, Lane 2: LAG-3 (human):Fc (human), (recombinant) (Prod. No. ALX-522-078).

Product Details

Alternative Name	Lymphocyte activation gene-3, FDC protein, CD223
Application	ICC, IHC, IP, WB
Clone	17B4
Formulation	Liquid. In PBS containing 10% glycerol and 0.02% sodium azide.
Host	Mouse
Immunogen	Synthetic peptide corresponding to 30 aa (GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY) from the first N-terminal D1 domain of human LAG-3 (lymphocyte activation gene-3).
Isotype	IgG1
Purity Detail	Purified.
Recommendation Dilutions/Conditions	Immunohistochemistry (frozen sections, 1:150)Western Blot (5µg/ml)Immunoprecipitation (10µg/ml)Suggested dilutions/conditions may not be available for all applications.Optimal conditions must be determined individually for each application.
Source	Purified from hybridoma tissue culture supernatant.
Species Reactivity	Human
Specificity	Recognizes the 30 aa extra-loop of the first N-terminal D1 domain of LAG-3.
UniProt ID	P18627
Worry-free Guarantee	This antibody is covered by our Worry-Free Guarantee.

Handling & Storage

Use/Stability	Stable for at least 6 months after receipt when stored as recommended.
Handling	Avoid freeze/thaw cycles.
Short Term Storage	+4°C
Long Term Storage	-20°C
Shipping	Blue Ice

Regulatory Status	RUO – Research Use Only

Durable response of anaplastic thyroid carcinoma to FS118, a bispecific LAG-3/PD-L1 antibody, after checkpoint inhibitor progression: a case report: M.J. Kroloff, et al.; J. Immunother. Cancer 10, e005225 (2022), Abstract
High Frequency Production of T Cell-Derived iPSC Clones Capable of Generating Potent Cytotoxic T Cells: S. Nagano, et al.; Mol. Ther. Methods Clin. Dev. 16, 126 (2019), Abstract — Full Text
Epigenomic-guided mass cytometry profiling reveals disease-specific features of exhausted CD8 T cells: B. Bengsch, et al.; Immunity 48, 1029 (2018), Application(s): CyTOF / Reactant(s) Human, Abstract — Full Text
PD-1/PD-L1 Blockade Enhances T-cell Activity and Antitumor Efficacy of Imatinib in Gastrointestinal Stromal Tumors: Seifert, A. M., Zeng, S., et al.; Clin. Cancer Res. 23, 454 (2017), Abstract
Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy: Klebanoff, C. A., Crompton, J. G., et al.; JCI Insight 2, (2017), Abstract
NK cell and IFN signatures are positive prognostic biomarkers for resectable pancreatic cancer: M. Hoshikawa, et al.; Biochem. Biophys. Res. Commun. 495, 2058 (2017), Abstract
Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions: N. Gulati, et al.; F1000Res. 4, 149 (2015), Application(s): Immunohistochemistry, Abstract — Full Text
Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients: L.G. Radvanyi, et al.; Clin. Cancer Res. 18, 6758 (2012), Application(s): FC using tumor-infiltrating lymphocytes (TIL), Abstract — Full Text
Human plasmacytoid dendritic cells induce CD8⁺ LAG-3⁺ Foxp3⁺ CTLA-4⁺ regulatory T cells that suppress allo-reactive memory T cells: Boor, P. P., Metselaar, H. J., et al.; Eur. J. Immunol. 41, 1663 (2011), Abstract
Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer: J. Matsuzaki, et al.; PNAS 107, 7875 (2010), Application(s): Blocking assays using tumor-infiltrating lymphocytes (TIL), Abstract — Full Text

Related Products

LAG-3 (human):Fc (human), (recombinant)

ALX-522-078

7 citations

Alternative Name	Lymphocyte activation gene-3, FDC protein, CD223
Purity	≥99% (SDS-PAGE)
Source	Produced in CHO cells. The sequence coding for the 4 extracellular Ig-like domains of human LAG-3 (D1-D4) is fused to the Fc portion of human IgG1.